Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy (BIBC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01652560|
Recruitment Status : Unknown
Verified July 2012 by LiNanlin,Ph.D, Chief Physician,Clinical Professor, Xijing Hospital.
Recruitment status was: Recruiting
First Posted : July 30, 2012
Last Update Posted : July 30, 2012
|Condition or disease||Intervention/treatment|
|Breast Cancer Bevacizumab Neoadjuvant Chemotherapy Molecular Targeted Therapy||Drug: bevacizumab|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy|
|Study Start Date :||June 2012|
|Estimated Primary Completion Date :||June 2014|
|Estimated Study Completion Date :||September 2014|
|bevacizumab combined neoadjuvant chemotherapy||
The patients will be treated with Avastin combined neoadjuvant chemotherapy
Other Name: Avastin
- Objective Response Rate [ Time Frame: From enrollment to disease progression ]From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
- overall response [ Time Frame: From enrollment to disease progression ]From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01652560
|Contact: Nanlin Li, Phdfirstname.lastname@example.org|
|Contact: Hongyu Xiao, Masteremail@example.com|
|Xijing Hospital ， Fourth Military Medical University||Recruiting|
|Xi`an, Shaanxi, China, 710032|
|Contact: Nanlin Li, Ph.D +86-186-2963-7041 firstname.lastname@example.org|
|Contact: Hongyu Xiao, Master +86-186-2963-7040 email@example.com|